Drugs / VP301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05698888 | Nov 2022 → Jun 2023 | plasma cell myeloma | Virtuoso BINco, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VP301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05698888 ↗ |
| Route | Intravenous | “VP301 administered as an IV infusion weekly for 6 weeks then every 2 weeks.” NCT05698888 ↗ |
| Target | CD38 | “VP301 is an afucosylated humanized Fc-modified immunoglobulin G1 (IgG1) bispecific antibody targeting CD38 and ICAM-1.” NCT05698888 ↗ |